PSIWM
SRPT icon

Paradigm Strategies in Wealth Management’s Sarepta Therapeutics SRPT Stock Holding History

Paradigm Strategies in Wealth Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-110
Closed -$9K – 208
2021
Q2 		$9K Hold
110
– – 0.01% 172
2021
Q1 		$8K Buy
+110
New +$10.2K 0.01% 173

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Paradigm Strategies in Wealth Management's SRPT Position: Q3 2021 in Review

Paradigm Strategies in Wealth Management sold out of Sarepta Therapeutics (SRPT) in Q3 2021, closing a stake of 110 shares — an estimated $9K sold.

Paradigm Strategies in Wealth Management first reported a position in SRPT in Q1 2021 and held it in 2 quarters. The position peaked at $9K in Q2 2021. 307 funds tracked by Wall St. Rank hold SRPT as of Q3 2021.

  • Paradigm Strategies in Wealth Management reported no remaining Sarepta Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Paradigm Strategies in Wealth Management sold 110 Sarepta Therapeutics shares in Q3 2021, an estimated $9K.
  • Paradigm Strategies in Wealth Management first reported a position in Sarepta Therapeutics in Q1 2021 and held it in 2 quarters.
  • Paradigm Strategies in Wealth Management's Sarepta Therapeutics position peaked at $9K in Q2 2021.
  • 307 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2021.

Based on Paradigm Strategies in Wealth Management's 13F filing for Q3 2021, filed 15 Oct 2021.